Results 111 to 120 of about 25,852 (227)

Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study

, 2004
This study was conducted to define a new maximum tolerated dose and the dose-limiting toxicity (DLT) of melphalan and autologous hematopoietic stem cell transplantation (AHSCT) when used with the cytoprotective agent amifostine. Fifty-eight patients with
Howard, D.S, R Nath, Phillips, G.L, E Reed, Wagner, J.L, Marshall, K.W, Nath, R, A Badros, Reed, E, R Fenton, Adams, V.R, J.L Wagner, Hale, G.A, Filicko, J, Meisenberg, B, D.H Vesole, Brunner, J, D Grosso, Takebe, N, N Flomenberg, J Filicko, Fenton, R, Vesole, D.H, Badros, A, Kniska, A, Reece, D.E, J Brunner, V.P Johnson, A Kniska, A.P Rapoport, V.R Adams, D.E Reece, Johnson, V.P, K.W Marshall, Flomenberg, N, Rapoport, A.P, B Meisenberg, G.L Phillips, G.A Hale, Grosso, D, D.S Howard, N Takebe   +41 more
core   +1 more source

Dynamic Immune Reconstitution and Clinical Outcomes of Three Different Protocols for Haploidentical Hematopoietic Stem Cell Transplantation

MedComm, Volume 7, Issue 6, June 2026.
This study compared clinical outcomes and immune reconstitution in haplo‐HSCT patients receiving PTCY (n = 45), ATG (n = 45), or PTCY+ATG (n = 45). The ATG group had superior OS (p = 0.029) and LFS (p = 0.034), with higher CD3+ and CD8+ T‐cell counts at 3 months.
Xiao‐Di Ma, Jie Ji, Zheng‐Li Xu, Lan‐Ping Xu, Yu Wang, Xiao‐Hui Zhang, Yu‐Qian Sun, Xiao‐Dong Mo, Yi‐Fei Cheng, Hui‐Dong Guo, Tian Dong, Xiao‐Jun Huang   +11 more
wiley   +1 more source

Injectable Dendrimer Hydrogel Delivers Melphalan in Both Conjugated and Free Forms for Retinoblastoma

We report the successful synthesis of an injectable dendrimer hydrogel (DH) carrying melphalan, a clinical drug for retinoblastoma treatment, in both conjugated and free forms.
Cooper, Remy C., Yang, Hu, Wang, Juan
core   +1 more source

Aldo-keto reductases contribute to melphalan resistance in MM cells.

, 2015
(A), Diagram showing markedly up-regulated levels of the AKR1C family in both SILAC and mRNA analyses, whereas members of other AKR subfamilies are not significantly altered. (B), Western analysis confirmed up-regulation of AKR1C2 and C3, but not C4. (C),
Antonio Sarno (279898), Aida Demirovic (279897), Kamila Anna Zub (279894), Geir Slupphaug (228532), Ida Ericsson (701671), Animesh Sharma (701670), Anders Sundan (440101), Shalini Rao (463953), Ole Nørregaard Jensen (167162), Mirta Mittelstedt Leal de Sousa (701669), Clifford Young (458349), Per Arne Aas (279895)   +11 more
core   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Melphalan [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, Volume 208, Issue 6, Page 2069-2078, June 2026.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

O tratamento e a sobrevida no mieloma múltiplo [PDF]

, 2011
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Ashihara, Carolina
core  

Encephalopathy complicating high-dose melphalan.

, 1999
High-dose melphalan (HDM) with peripheral blood stem cell transplant (PBSCT) is a common treatment for patients with multiple myeloma (MM) and more recently also with AL amyloidosis (ALA).
Schuh, A, Dandridge, J, Schuh, Anna, Littlewood, TJ, Haydon, P   +4 more
core   +1 more source

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

British Journal of Haematology, Volume 208, Issue 6, Page 2134-2142, June 2026.
Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less ...
Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima   +9 more
wiley   +1 more source